Journal of Anaesthesia & Critical Care Case Reports

Vol 8 | Issue 3 | September-December 2022 | Page: 09-11 | David Guz, Angela Johnson, Connor McNamara

DOI: 10.13107/jaccr.2022.v08i03.207

Author: David Guz [1], Angela Johnson [2], Connor McNamara [2]

[1] Detroit Medical Center/Wayne State University, Detroit, MI 48201.
[2] University Hospitals Cleveland Medical Center, 11100 Euclid Ave., Cleveland, OH 44106.

Address of Correspondence
Dr. David Guz,
Detroit Medical Center/Wayne State University, 3990 John R St., Detroit, MI 48201.
E-mail: DGuz@dmc.org

Abstract

We describe a patient with minimal cardiac risk factors who developed transient myocardial ischemia and complete heart block demonstrated on electrocardiography in the setting of recent esophagectomy likely caused by coronary vasospasm. The ischemic changes on ECG resolved within minutes following administration of glycopyrrolate, suggesting increased vagal tone leading to coronary vasospasm as a possible etiology. Coronary vasospasm is an uncommon cause of myocardial ischemia in the perioperative period. Anesthesiologists should be aware of coronary vasospasm as a clinical entity and its management when confronted with new-onset myocardial ischemia in the perioperative period. Written informed consent was obtained from patient prior to submission of this case report for publication.
Keywords: Coronary vasospasm, Esophagectomy, Major adverse cardiac event

References

(1) Nagayoshi Y, Kawano H, Kojima S., et al. Significance of Coronary Vasospasm in the Periopera-tive Management of Non-Cardiac Surgery. Circ J. 2012; 76(8):1965-1971. doi:10.1253/circj.cj-11-1278
(2) Smilowitz NR, Gupta N, Ramakrishna H, Guo Y, Berger JS, Bangalore S. Perioperative Major Ad-verse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery. JAMA Cardiol. 2017; 2(2):181-187. doi:10.1001/jamacardio.2016.4792
(3) Ford MK. Systematic Review: Prediction of Perioperative Cardiac Complications and Mortality by the Revised Cardiac Risk Index. Ann Intern Med. 2010; 152(1):26-35. doi:10.7326/0003-4819-152-1-201001050-00007
(4) Ahn J-M, Lee KH, Yoo S-Y. et al. Prognosis of Variant Angina Manifesting as Aborted Sudden Cardiac Death. J Am Coll Cardiol. 2016; 68(2):137-145.
(5) Beltrame JF, Crea F, Kaski JC. et al. International standardization of diagnostic criteria for vaso-spastic angina. Eur Heart J. 2015; 38(33):2565-2568. doi:10.1093/eurheartj/ehv351
(6) Suzuki S, Yoshimura M, Nakayama M et al. A novel genetic marker for coronary spasm in women from a genome-wide single nucleotide polymorphism analysis. Pharmacogenet Genomics. 2007; 17(11):919-30.
(7) Kusama Y, Kodani E, Nakagomi A et al. Variant angina and coronary artery vasospasm: the clinical spectrum, pathophysiology, and management. J Nippon Med Sch.. 2011; 78(1):4-12.
(8) Takaoka K, Yoshimura M, Ogawa H. et al. Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking. Int J Cardiol. 2000; 72(2):121-126. doi:10.1016/s0167-5273(99)00172-2
(9) Yasue H, Horio Y, Nakamura N. et al. Induction of coronary artery spasm by acetylcholine in pa-tients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation. 1986; 74(5):955-963. doi:10.1161/01.cir.74.5.955
(10) Stern S, Bayes de Luna A. Coronary Artery Spasm. Circulation. 2009; 119(18):2531-2534. doi:10.1161/CIRCULATIONAHA.108.843474
(11) Satake K, Lee J-D, Shimizu H, Ueda T, Nakamura T. Relation Between Severity of Magnesium Deficiency and Frequency of Anginal Attacks in Men With Variant Angina. J Am Coll Cardiol. 1996; 28(4):897-902. doi:10.1016/s0735-1097(96)00256-2
(12) Montalescot G, Sechtem U, Achenbach S. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013; 34(38):2949-3003. doi:10.1093/eurheartj/eht296
(13) Miwa K, Fujita M, Miyagi Y. Beneficial effects of smoking cessation on the short-term prog-nosis for variant angina — validation of the smoking status by urinary cotinine measurements. Int J Cardiol. 1994; 44(2):151-156. doi:10.1016/0167-5273(94)90019-1
(14) Hom GA, Brent BN. Coronary artery vasospasm during treatment with intravenous nitroglyc-erin. Cathet Cardiovasc Diagn. 1985; 11(4):423-426. doi:10.1002/ccd.1810110412
(15) Hung M-J, Hu P, Hung M-Y. Coronary Artery Spasm: Review and Update. Int J Med Sci. 2014; 11(11):1161-1171. doi:10.7150/ijms.9623
(16) Matsue Y, Suzuki M, Nishizaki M, Hojo R, Hashimoto Y, Sakurada H. Clinical Implications of an Implantable Cardioverter-Defibrillator in Patients With Vasospastic Angina and Lethal Ventricu-lar Arrhythmia. J Am Coll Cardiol. 2012; 60(10):908-913. doi:10.1016/j.jacc.2012.03.070
(17) Stawicki SP, Prosciak MP, Gerlach AT. Atrial fibrillation after esophagectomy: an indicator of postoperative morbidity. Gen Thorac Cardiovasc Surg. 2011; 59(6):399-405. doi:10.1007/s11748-010-0713-9
(18) Kongsrud F, Sponheim S. A comparison of atropine and glycopyrrolate in anesthetic practice. Acta Anesthesiol Scand. 1982; 26(6):620-5.

(Abstract Text HTML)     (Download PDF)